Beyond declining mortality: toward equitable cardiometabolic prevention

Q: What is the clinical evidence from this study?

Study design: Review. Population: Type 2 diabetes. Intervention: SGLT2 inhibitors and GLP-1 receptor agonists vs. Traditional glucocentric management.

Q: What does this research mean for the field?

The management of type 2 diabetes has shifted from a glucocentric paradigm to prioritizing cardiorenal organ protection using SGLT2 inhibitors and GLP-1 receptor agonists to reduce macrovascular and renal complications. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

Moon-Seung Soh

doi:10.36011/cpp.2026.8.e6

July 28, 2026Cardiovascular Prevention and PharmacotherapyOpen Access

Beyond declining mortality: toward equitable cardiometabolic prevention

View Full Paper

Ask AI

Bookmark

Share

Why the study?

Intensive glycemic control trials showed benefits limited to microvascular diseases rather than cardiorenal events, emphasizing the need for comprehensive risk factor management and a shift toward cardiorenal outcome-oriented care in type 2 diabetes.

Key Points

To review the evolution of type 2 diabetes management from glucocentric glycemic control toward comprehensive cardiorenal risk reduction and organ protection.
Synthesized evidence from landmark cardiovascular outcome trials evaluating intensive glycemic control, SGLT2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors in patients with type 2 diabetes.
Assessed shifts in clinical practice recommendations from global diabetes associations and the Korean Diabetes Association regarding cardiorenal comorbidity management.
Intensive glycemic control historically demonstrated risk reductions limited to microvascular complications, failing to prevent macrovascular outcomes, heart failure, or mortality.
Cardiovascular outcome trials demonstrated significant reductions in events with SGLT2 inhibitors (EMPA-REG HR 0.86, 95% CI 0.74–0.99; CANVAS HR 0.86, 95% CI 0.75–0.97) and GLP-1 receptor agonists (SUSTAIN-6 HR 0.74, 95% CI 0.58–0.95; LEADER HR 0.87, 95% CI 0.78–0.97).
In the SAVOR-TIMI 53 trial, saxagliptin therapy led to a significant increase in hospitalizations due to heart failure compared to placebo (3.5% vs. 2.8%, P=0.007).

Structured PICO

P

Population

Patients with type 2 diabetes

I

Intervention

Antidiabetic medications, specifically SGLT2 inhibitors and GLP-1 receptor agonists

Implication

The management of type 2 diabetes has shifted from strictly lowering blood glucose to prioritizing cardiovascular and renal organ protection using SGLT2 inhibitors and GLP-1 receptor agonists.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Moon-Seung Soh (2026) conducted a review in Type 2 diabetes. SGLT2 inhibitors and GLP-1 receptor agonists vs. Traditional glucocentric management was evaluated.

synapsesocial.com/papers/6a6af4d560e2b924d3ea04c3 https://doi.org/10.36011/cpp.2026.8.e6

View Full Paper

Ask AI

Bookmark

Share

Beyond declining mortality: toward equitable cardiometabolic prevention

Key Points

Structured PICO

Implication

Abstract

Discussion

Cite This Study

Beyond declining mortality: toward equitable cardiometabolic prevention

Key Points

Structured PICO

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from Cardiovascular Prevention and Pharmacotherapy

Keep reading

More related papers

More from Cardiovascular Prevention and Pharmacotherapy